{
    "nctId": "NCT02580279",
    "briefTitle": "Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy",
    "officialTitle": "Phase II Study of Topical Epigallocatechin-3-gallate (EGCG) in Patients With Breast Cancer Receiving Adjuvant Radiotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Dermatitis, Prevention & Control, Epigallocatechin Gallate",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 68,
    "primaryOutcomeMeasure": "Superiority of EGCG in reducing Grade II or more dermatitis as assessed by Radiation Therapy Oncology Group (RTOG) scores in patients with breast cancer receiving radiation",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 eighteen years\n* Eastern Cooperative Oncology Group performance status of 0-1\n* Normal hematologic, hepatic function and renal values\n* Forced expiratory volume 1 \\>800 cc\n\nExclusion Criteria:\n\n* The presence of rash or unhealed wound in the radiation field\n* A known allergy or hypersensitivity to EGCG\n* Pregnancy or lactation\n* History of/current connective tissue disorder\n* Prior radiation to the thorax",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}